From: Modelling the cost-effectiveness of pay-for-performance in primary care in the UK
QOF effects beyond mortality | How long QOF mortality benefit is sustained if QOF discontinued** | |||||
---|---|---|---|---|---|---|
Non-fatal outcomes | Increased drug costs | No waning | 1-year waning | 3-year waning | 5-year waning | 10-year waning |
Included | Included | 49,362* | 51,970 | 57,616 | 63,765 | 81,428 |
Included | Not included | 48,768 | 51,347 | 56,931 | 63,011 | 80,478 |
Not included | Included | 80,515 | 84,323 | 92,565 | 101,535 | 127,281 |
Not included | Not included | 79,657 | 83,424 | 91,575 | 100,446 | 125,907 |